RxDoctor Payments Data

Muthusamy Muthiah, MD

Cardiovascular Disease · Pomona, CANPI 1679541148

Payments from drug & device makers

$2,405in general payments, 2019–2025

Across 127 payments — averaging $18.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$687
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$340
  • Merck$210
  • Amarin Pharma, Inc.$196
  • Johnson & Johnson$174
  • Abbott$162
  • plus $638 from 19 others

What the payments were for

  • Food & beverage$2,38399%
  • Education$221%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,405 in reported general payments places this provider in the 45th percentile of 2,184 cardiovascular disease providers in California.

See all cardiovascular disease providers in California

Medicare billing

Part B allowed, 2024
$526,703
Medicare patients
1,153
Services billed
4,611

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban515$556,232
EntrestoSacubitril/Valsartan283$307,627
XareltoRivaroxaban187$193,865
FarxigaDapagliflozin Propanediol102$93,040
BrilintaTicagrelor33$32,427
JardianceEmpagliflozin26$27,965
Repatha SureclickEvolocumab27$14,417
VascepaIcosapent Ethyl16$12,693
Praluent PenAlirocumab19$10,487
Metoprolol Succinate366$5,050
Atorvastatin Calcium404$3,998
Carvedilol291$2,840
Losartan Potassium216$2,296
Amlodipine Besylate300$2,220
Rosuvastatin Calcium154$2,142

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$75$556,232515 claims
NovartisEntresto$687$307,627283 claims
Johnson & JohnsonXarelto$174$193,865187 claims
AstraZenecaFarxiga, Brilinta$48$125,467135 claims
Boehringer IngelheimJardiance$32$27,96526 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 2,184 cardiovascular disease providers in California.

Other cardiovascular disease in Pomona

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →